Content area

|
|

Immunterapi med checkpointhæmmere og endokrinologiske bivirkninger

Forfatter(e)
Line Bisgaard Jørgensen1, Lars Bastholt2 & Knud Yderstræde1 1) Endokrinologisk Afdeling, Odense Universitetshospital 2) Onkologisk Afdeling, Odense Universitets-hospital Ugeskr Læger 2017;179:V05170362
Reference: 
Ugeskr Læger 2017;179:V05170362
Blad nummer: 
Sidetal: 
2-6
Immune checkpoint inhibitors and endocrinological side effects
Immune checkpoint inhibitors including anti-cytotoxic T-lymphocyte-associated antigen-4 and anti-programmed cell death-1 have revolutionized cancer therapy but have also induced serious immune-related adverse events including hormonal dysfunction. The objective of this review is to characterize the incidence, clinical presentation, management and prognosis of the endocrine-related adverse events including hypophysitis, thyroid dysfunction and diabetes mellitus. Combination therapy is associated with an increased risk of adverse events. We recommend close monitoring of the hormone levels and glycaemic status during and a year after treatment.
Du skal være logget ind for at læse denne artikel
Log ind

Right side

af Erik Jakob Møller | 15/12
12 kommentarer
af Trine Cecilie Jeppesen | 15/12
1 Kommentar
af Lars Linnet | 14/12
1 Kommentar
af Niels Ejnar Bie | 14/12
1 Kommentar
af John Erik Bleibach | 14/12
1 Kommentar
af Mogens Stubkjær Hüttel | 14/12
35 kommentarer
af Lene Vejen Christiansen | 13/12
3 kommentarer
af Christian F. Asmussen | 13/12
7 kommentarer